This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Analysis Of The U.S. Neurostimulation Market

NEW YORK, Feb. 19, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Analysis of the U.S. Neurostimulation Market

http://www.reportlinker.com/p01099851/Analysis-of-the-US-Neurostimulation-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment

This research service looks at the neurostimulation devices market in the United States. The market is expected to see many technology advancements in the next decade. Therefore, a thorough understanding of revenue forecasts, unit forecasts, technological advances, and pricing analyses are provided for the market's various segments including: spinal cord stimulators, deep brain stimulators, vagus nerve stimulators, and sacral nerve stimulators. Furthermore, market engineering measurements, industry challenges, drivers, restraints, company profiling, product profiling, and technology trends are covered along with an analysis of the market's highly competitive landscape. The base year is 2012; the forecast period extends through 2018.

Executive Summary•The size of the total neurostimulation market was estimated to be $X million in 2012 and is projected to grow at a compound annual growth rate (CAGR) of X percent over the next seven years, to reach $X million in 2018.•In 2012, the total revenue generated by sales of neurostimulator devices in the United States was estimated to represent X percent increase over 2011 revenue.•Competitors generating the highest revenue in the U.S. neurostimulation market in 2012 were Medtronic, St. Jude Medical, Boston Scientific Corp., and Cyberonics. Together, they were estimated to contribute Xpercent of total market revenue.•The Spinal Cord Stimulators (SCS) market is the largest neurostimulation segment, constituting X percent of the U.S. neurostimulation market and likely to grow at a significant CAGR of X per between 2012 and 2018.•In 2012, the other neurostimulation segments, including Deep Brain Stimulators (DBS), Vagus Nerve Stimulators (VNS), and Sacral Nerve Stimulators (SNS), were estimated to contribute Xpercent, Xpercent, andXpercent respectively.•In 2012, an estimated X neurostimulator implant procedures were performed in the United States.•Neurostimulator implant procedures are projected to grow at a CAGR of X percent from 2012 to 2018, reaching X in 2018.•The rising prevalence of diseases, growing demand for new alternative therapies to meet the demands of unmet clinical needs, and an aging baby-boomer population in the United States are likely to drive growth in the market.•However, regulatory approvals and insurance reimbursement pose major challenges for neurostimulator manufacturers in the United States.•Market participants may need to focus on developing disruptive technologies to further enhance the product or the technology adoption rate.

TABLE OF CONTENTS Executive Summary 5Market Overview 10Total Neurostimulation Market 18•Industry Challenges 20•External Challenges: Drivers and Restraints 26•Forecasts and Trends 34•Demand Analysis 43•Market Share and Competitive Analysis 46Strategic Pipeline Assessment 57Company Profiles and Industry Highlights of Top Neurostimulation Market Participants 62Segment Analysis 74•Spinal Cord Stimulators Segment Breakdown 77•Deep Brain Stimulators Segment Breakdown 103•Vagus Nerve Stimulators Segment Breakdown 129•Sacral Nerve Stimulators Segment Breakdown 153Strategic Recommendations and Conclusions 180The Last Word 185Appendix 188

To order this report: Surgical_Equipment Industry: Analysis of the U.S. Neurostimulation Market

Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs